ALCMI is committed to identifying and validating optimal molecular targets to help facilitate the development of effective, targeted therapies. ALCMI seeks to accelerate the advancement of promising compounds/agents from the laboratory to the clinic, and will develop correlative science collaborations in parallel with investigator-initiated, cooperative group, and industry-sponsored Phase I-III clinical trials.
